Company: KROS
Filing Date: 2025-05-09
Form Type: DEFA14A
Source: 0001104659-25-046272
Chunk: 4

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-09
Form: DEFA14A
Chunk 4
---
 and other risks are described more fully in Keros’ filings
with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s
Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025, and its other documents subsequently filed with or furnished
to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to
the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that
exist after the date on which they were made.

There can be no assurance that the review of strategic alternatives
will result in the Company pursuing a transaction or any other strategic outcome. There is no deadline or definitive timetable set for
completion of the strategic alternatives review process. Keros intends to provide a preliminary update regarding the status of the process
within 60 days of its original announcement of the process on April 10, 2025. Otherwise, Keros does not intend to disclose developments
related to the process unless and until it determines that further disclosure is appropriate or necessary.

Important Additional Information and Where to Find It

On April 23, 2025, the Company filed a definitive proxy statement
on Schedule 14A (the "Proxy Statement") and form of accompanying proxy card with the SEC in connection with its 2025 Annual
Meeting and its solicitation of proxies for the Company’s director nominees and for other matters to be voted on. The Company may
also file other relevant documents with the SEC regarding its solicitation of proxies for the 2025 Annual Meeting. This communication
is not a substitute for any proxy statement or other document that the Company has filed or may file with the SEC in connection with any
solicitation by the Company. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS
FILED WITH, OR FURNISHED TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a
copy of the Proxy Statement and any amendments or supplements to the Proxy Statement and any other relevant documents filed by the Company
with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s
website at https://ir.kerostx.com/financials-filings/sec-filings